Imfinzi may be used to treat patients with advanced cancer bladder whose illness has advanced despite chemotherapy. The average wholesale acquisition price for the drug is about $15,000 a month, according to AstraZeneca.
While this decision marks the first approved use for the immunotherapy drug, AstraZeneca is also exploring Imfinzi’s efficacy to treat lung cancer.
More articles on supply chain:
FDA approves new osteoporosis drug
Supply chain tip of the week: Target services — not supplies — for cost savings
FDA approves RFID device to locate breast lumps
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.